How Generic Entry Drove Lipitor's Price Drop
Lipitor (atorvastatin), Pfizer's blockbuster statin for cholesterol, launched in 1996 with peak U.S. sales over $12 billion annually. Its patent expired December 30, 2011, allowing generic atorvastatin to enter the market. Competition immediately slashed prices: within months, generic versions cost 80-90% less than branded Lipitor, dropping from about $4 per pill to under 10 cents.[1][2]
Ranbaxy Laboratories won FDA approval for the first generic in 2011 after a long patent fight, but quality issues delayed full launch until 2012. Pfizer settled lawsuits with multiple generics makers (e.g., Teva, Mylan, Watson) via authorized generic deals, which accelerated competition while limiting some rivals temporarily.[3]
Why Did Prices Fall So Fast After Multiple Entrants?
With 17 generic manufacturers approved by 2013, supply flooded the market. Average wholesale price fell 95% from 2011 to 2014, per FDA data, as firms undercut each other on price to capture share in a commoditized market.[1] Generic penetration hit 90% within a year, forcing Lipitor's brand price to plummet too.
| Year | Branded Lipitor (30-day supply, ~$USD) | Generic Atorvastatin Equivalent |
|------|---------------------------------------|-------------------------------|
| 2011 | ~$180 | N/A (pre-entry) |
| 2012 | ~$140 | ~$15 |
| 2013 | ~$20 | ~$8 |
| 2018 | ~$10 | ~$1-2[2][4] |
What Kept Prices High Initially?
Pre-expiry, Pfizer defended Lipitor with 133 Orange Book patents and pediatric exclusivity until 2011. Authorized generics—Pfizer's own cheap versions via partners—captured 20-30% market share post-launch, slowing pure generic erosion and stabilizing revenue at $2-3 billion yearly through 2013.[3] Reverse payments in settlements (e.g., $68 million to Ranbaxy) delayed some challengers until 2012, drawing FTC antitrust scrutiny.[5]
How Does Lipitor Compare to Other Blockbusters?
Unlike Lipitor's steep drop, drugs like Nexium saw slower declines due to fewer generics initially. Lipitor's case exemplifies "generic shock," where high competition yields near-zero margins long-term—today's generics cost pennies amid over 20 ANDA approvals.[1][6]
Current Pricing and Ongoing Competition
U.S. retail generics now average $0.20-$0.50 for 30 days (GoodRx data), with further drops from mail-order and chains. No major patents block generics; check DrugPatentWatch.com for latest expirations on formulations.[7] International markets mirrored this: UK prices fell 85% post-2012 entry.[2]
Sources:
[1] FDA Generic Competition Report (2019) https://www.fda.gov/media/133509/download
[2] IMS Health (now IQVIA) data via NIH https://pubmed.ncbi.nlm.nih.gov/23397519/
[3] FTC v. Actavis (2013) Supreme Court case summary https://www.supremecourt.gov/opinions/12pdf/12-416_m6hn.pdf
[4] GoodRx pricing trends https://www.goodrx.com/atorvastatin
[5] FTC settlement reports https://www.ftc.gov/news-events/press-releases/2010/04/pfizer-pay-68-million-settle-ftc-charges-pay-delay-deal
[6] GAO Generic Drug Report (2021) https://www.gao.gov/assets/gao-21-265.pdf
[7] DrugPatentWatch.com https://www.drugpatentwatch.com/p/tradename/LIPITOR